Dose response effects of lisdexamfetamine dimesylate treatment in adults with
ADHD: an exploratory study.
Author(s): Faraone SV, Spencer TJ, Kollins SH, Glatt SJ, Goodman D.
Affiliation(s): SUNY Upstate Medical University, Syracuse, NY 13210, USA. faraones@upstate.edu
Publication date & source: 2012, J Atten Disord. , 16(2):118-27
OBJECTIVE: To explore dose-response effects of lisdexamfetamine dimesylate (LDX)
treatment for ADHD.
METHOD: This was a 4-week, randomized, double-blinded, placebo-controlled,
parallel-group, forced-dose titration study in adult participants, aged 18 to 55
years, meeting Diagnostic and Statistical Manual of Mental Disorders (4th ed.,
text rev.) criteria for ADHD.
RESULTS: Nearly all participants assigned to an LDX dose achieved their assigned
dose with the exception of about 4% of participants assigned to the 50 mg or 14%
assigned to the 70 mg doses. Higher doses of LDX led to greater improvements in
ADHD-rating scale scores, independent of prior pharmacotherapy. This was evident
for both inattentive and hyperactive-impulsive symptoms. The authors found some
evidence for an interaction between LDX dose and baseline severity of ADHD
symptoms.
CONCLUSION: For LDX doses between 30 and 70 mg/d, the dose-response efficacy
effect for LDX is not affected by prior pharmacotherapy, but patients with a
greater severity of illness may benefit more from higher doses, especially for
hyperactive-impulsive symptoms. The results do not provide information about
doses above 70 mg/d, which is the maximum approved dose of LDX and the highest
dose studied in ADHD clinical trials.
|